These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 8346714

  • 1. Amplification of eosinophilia by melatonin during the immunotherapy of cancer with interleukin-2.
    Lissoni P, Ardizzoia A, Tisi E, Rossini F, Barni S, Tancini G, Conti A, Maestroni GJ.
    J Biol Regul Homeost Agents; 1993; 7(1):34-6. PubMed ID: 8346714
    [Abstract] [Full Text] [Related]

  • 2. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
    Lissoni P, Brivio F, Brivio O, Fumagalli L, Gramazio F, Rossi M, Emanuelli G, Alderi G, Lavorato F.
    J Biol Regul Homeost Agents; 1995; 9(1):31-3. PubMed ID: 8553906
    [Abstract] [Full Text] [Related]

  • 3. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
    Lissoni P, Malugani F, Malysheva O, Kozlov V, Laudon M, Conti A, Maestroni G.
    Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
    [Abstract] [Full Text] [Related]

  • 4. Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients.
    Lissoni P, Barni S, Ardizzoia A, Brivio F, Tancini G, Conti A, Maestroni GJ.
    J Biol Regul Homeost Agents; 1992 Aug; 6(4):132-6. PubMed ID: 1296454
    [Abstract] [Full Text] [Related]

  • 5. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin.
    Lissoni P, Tisi E, Brivio F, Ardizzoia A, Crispino S, Barni S, Tancini G, Conti A, Maestroni GJ.
    J Biol Regul Homeost Agents; 1991 Aug; 5(4):154-6. PubMed ID: 1803863
    [Abstract] [Full Text] [Related]

  • 6. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
    Lissoni P, Bolis S, Brivio F, Fumagalli L.
    Anticancer Res; 2000 Aug; 20(3B):2103-5. PubMed ID: 10928160
    [Abstract] [Full Text] [Related]

  • 7. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
    Lissoni P, Barni S, Ardizzoia A, Olivini G, Brivio F, Tisi E, Tancini G, Characiejus D, Kothari L.
    J Biol Regul Homeost Agents; 1993 Aug; 7(4):121-5. PubMed ID: 8023699
    [Abstract] [Full Text] [Related]

  • 8. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension.
    Lissoni P, Brivio F, Barni S, Tancini G, Cattaneo G, Archili C, Conti A, Maestroni GJ.
    Anticancer Res; 1990 Aug; 10(6):1759-61. PubMed ID: 2285255
    [Abstract] [Full Text] [Related]

  • 9. Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study.
    Lissoni P, Barni S, Brivio F, Rossini F, Fumagalli L, Tancini G.
    J Biol Regul Homeost Agents; 1995 Aug; 9(2):52-4. PubMed ID: 9127633
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-2, melatonin and interleukin-12 as a possible neuroimmune combination in the biotherapy of cancer.
    Lissoni P, Pittalis S, Rovelli F, Vigorè L, Roselli MG, Brivio F.
    J Biol Regul Homeost Agents; 1995 Aug; 9(2):63-6. PubMed ID: 9127635
    [Abstract] [Full Text] [Related]

  • 11. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
    Lissoni P, Fumagalli L, Paolorossi F, Rovelli F, Roselli MG, Maestroni GJ.
    J Biol Regul Homeost Agents; 1997 Aug; 11(3):119-22. PubMed ID: 9498162
    [Abstract] [Full Text] [Related]

  • 12. Melatonin as a new possible anti-inflammatory agent.
    Lissoni P, Rovelli F, Meregalli S, Fumagalli L, Musco F, Brivio F, Brivio O, Esposti G.
    J Biol Regul Homeost Agents; 1997 Aug; 11(4):157-9. PubMed ID: 9582617
    [Abstract] [Full Text] [Related]

  • 13. Prevention of interleukin-2-induced thrombocytopenia during the immunotherapy of cancer by a concomitant administration of the pineal hormone melatonin.
    Bregani ER, Lissoni P, Rossini F, Barni S, Tancini G, Brivio F, Conti A, Maestroni GJ.
    Recenti Prog Med; 1995 Jun; 86(6):231-3. PubMed ID: 7624582
    [Abstract] [Full Text] [Related]

  • 14. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
    Lissoni P, Brivio F, Fumagalli L, Messina G, Vigoré L, Parolini D, Colciago M, Rovelli F.
    Anticancer Res; 2008 Jun; 28(2B):1377-81. PubMed ID: 18505083
    [Abstract] [Full Text] [Related]

  • 15. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P, Vaghi M, Ardizzoia A, Malugani F, Fumagalli E, Bordin V, Fumagalli L, Bordoni A, Mengo S, Gardani GS, Tancini G.
    In Vivo; 2002 Jun; 16(2):93-6. PubMed ID: 12073777
    [Abstract] [Full Text] [Related]

  • 16. Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin.
    Lissoni P, Barni S, Tancini G, Brivio F, Tisi E, Zubelewicz B, Braczkowski R.
    J Biol Regul Homeost Agents; 1994 Jun; 8(4):126-9. PubMed ID: 7660855
    [Abstract] [Full Text] [Related]

  • 17. A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients.
    Lissoni P, Barni S, Tancini G, Rovelli F, Ardizzoia A, Conti A, Maestroni GJ.
    Oncology; 1993 Jun; 50(6):399-402. PubMed ID: 8233281
    [Abstract] [Full Text] [Related]

  • 18. A study of immunoendocrine strategies with pineal indoles and interleukin-2 to prevent radiotherapy-induced lymphocytopenia in cancer patients.
    Lissoni P, Rovelli F, Brivio F, Fumagalli L, Brera G.
    In Vivo; 2008 Jun; 22(3):397-400. PubMed ID: 18610754
    [Abstract] [Full Text] [Related]

  • 19. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
    Lissoni P, Barni S, Tancini G, Ardizzoia A, Ricci G, Aldeghi R, Brivio F, Tisi E, Rovelli F, Rescaldani R.
    Br J Cancer; 1994 Jan; 69(1):196-9. PubMed ID: 8286206
    [Abstract] [Full Text] [Related]

  • 20. Is there a role for melatonin in supportive care?
    Lissoni P.
    Support Care Cancer; 2002 Mar; 10(2):110-6. PubMed ID: 11862501
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.